anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although the global prevalence of primary angle-closure glaucoma (PACG) is less than half that of primary open-angle glaucoma, the risk of serious bilateral visual impairment caused by PACG is three times more than that of primary open-angle glaucoma. PACG is the leading cause of irreversible blindness all over the world, characterized by closure of the anterior chamber angle. Primary angle closure suspect (PACS), the earliest stage of primary angle-closure diseases (PACD), is defined as no less than three quadrants of appositional contact between the peripheral iris and posterior trabecular meshwork on gonioscopy. The progression from PACS to primary angle closure (PAC) was defined as elevated intraocular pressure (IOP) and the presence of peripheral anterior synechiae (PAS). PACG was characterized as PAC together with evidence of glaucomatous optic neuropathy (GON) or glaucomatous visual field defects. It is estimated that by 2040, the number of PACG cases worldwide will reach 32 million, of which Asian cases account for a large proportion. Therefore, a better understanding the natural history of PACD may play an important role in preventing devastating visual impairment.

Previous studies have reported the prevalence of PAC and PACG was 1%-11.3%, but longitudinal reports on its incidence and progression of earlier stages of angle closure that precede PAC/PACG are scarce, especially for Asian population. A Danish study demonstrated that the rate of progression from the condition of shallow anterior chamber to PACG was 16% at ten-year follow-up. Studies in Asia showed that the rate of PACS progress to PAC or PACG was range from 5.3% to 25.5%. And the risk factors of progression included bilateral PACS, smaller angle width, shorter angle open distance, larger iris curvature, and older age. Of note, these studies evaluated the anterior chamber of subjects with examinations including IOLMaster, A scan, and anterior segment-optical coherence tomography (AC-OCT). However, the ultrasound biomicroscopy (UBM), which is most valuable examination in the evaluation of patients with angle closure, was not used. Thus, details such as the volume of the ciliary body, the degree of ciliary anterior rotation, and parameters related to the vitreous zonule (VZ) might have been neglected. In the past, laser peripheral iridotomy (LPI) was considered to be a precaution against progression of PACD, but a few studies postulated that the benefit of prophylactic LPI was limited for PACS. If PACS with high progression risks can be accurately identified, LPI could be applied to high-risk PACS patients rather than all. Therefore, the research on precise risk analysis for PACS progression is imperative.

The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.
FIELD: pharmaceutics. SUBSTANCE: invention relates to technology of production of balsamic remedies based on oil-alcohol natural material extracts. Preliminarily prepared at weight ratio 1:2 to water and filtered aqueous cabbage decoction is extracted with rectified alcohol at decoction-to-alcohol weight ratio 27:73. Extract solution (3 wt parts) is used to extract bovine bones (1 wt part) at 30-35 C. Resulting extract is filtered and used (10 wt parts) for extracting divided garlic (1 wt part) at 20-25 C. Transparent part of extract obtained is decanted and sealed. EFFECT: increased stability and biological activity. 5 cl, 3 ex
Decompressive hemicraniectomy (DHC) is a critical procedure used to alleviate elevated intracranial pressure (ICP) in emergent situations. It is typically performed to create space for the swelling brain and to prevent dangerous and potentially fatal increases in ICP. DHC is indicated for pathologies ranging from MCA stroke to traumatic subarachnoid hemorrhage-essentially any cause of refractory brain swelling and elevated ICPs. Scalp incisions for opening and closing the soft tissues during DHC are crucial to achieve optimal outcomes by promoting proper wound healing and minimizing surgical site infections (SSIs). Though the reverse question mark (RQM) scalp incision has gained significant traction within neurosurgical practice, alternatives-including the retroauricular (RA) and Kempe incisions-have been proposed. As choice of technique can impact postoperative outcomes and complications, we sought to compare outcomes associated with different scalp incision techniques used during DHC. We queried three databases according to PRISMA guidelines in order to identify studies comparing outcomes between the RQM versus "alternative" scalp incision techniques for DHC. Our primary outcome of interest in the present study was postoperative wound infection rates according to scalp incision type. Secondary outcomes included estimated blood loss (EBL) and operative duration. We identified seven studies eligible for inclusion in the formal meta-analysis. The traditional RQM technique shortened operative times by 36.56 min, on average. Additionally, mean EBL was significantly lower when the RQM scalp incision was used. Postoperatively, there was no significant association between DHC incision type and mean intensive care unit (ICU) length of stay (LOS), nor was there a significant difference in predisposition to developing wound complications or infections between the RQM and retroauricular/Kempe incision cohorts. Superficial temporal artery (STA) preservation and reoperation rates were collected but could not be analyzed due to insufficient number of studies reporting these outcomes. Our meta-analysis suggests that there is no significant difference between scalp incision techniques as they relate to surgical site infection and wound complications. At present, it appears that outcomes following DHC can be improved by ensuring that the bone flap is large enough to enable sufficient cerebral expansion and decompression of the temporal lobe, the latter of which is of particular importance. Although previous studies have suggested that there are several advantages to performing alternative scalp incision techniques during DHC, the present study (which is to our knowledge the first to meta-analyze the literature on outcomes in DHC by scalp incision type) does not support these findings. As such, further investigations in the form of prospective trials with high statistical power are merited.
Osteoarthritis (OA) knee is one of the most common chronic degenerative conditions that imposes clinical and economic burdens on individuals and societies worldwide. Previous studies showed vitamin D levels correlated positively with lean muscle mass and grip strength, implying that vitamin D supplementation may improve muscle health in knee OA subjects. This randomized controlled trial (RCT) aims to compare the effects of vitamin D supplementation on knee muscle strength, physical function, pain, and sarcopenia status in patients with end-stage knee OA. Patients and outcome assessors will be blinded to group allocation. Fifty-six end-stage knee OA patients with vitamin D insufficiency fulfilling our inclusion criteria will be invited to participate in this study. Patients will be randomly assigned to take vitamin D supplementation (4,000 IU capsule daily) or placebo for six months. Measurements will be taken at baseline, three and six-month after the commencement of the vitamin D supplement, and 6-month after the interventional period. The primary outcome includes the isometric quadriceps and hamstring muscle strength measured by a hand-held dynamometer. Secondary outcomes include pain, performance-based and self-reported physical function and sarcopenia status. The success of this study will provide scientific evidence of whether the relatively cheap and well-tolerated vitamin D supplement can improve quadriceps muscle strength, physical function, pain symptoms, and sarcopenia status of this increasingly large population for end-stage knee OA patients. The study has great clinical significance given Hong Kong's lengthy and growing waiting list for complete knee replacement procedures. Trial registration: The trial was registered on clinicaltrials.gov (NCT05981534) on 31st July 2023.
Laryngeal cancer (LC) is the second most common head and neck cancer and has a decreasing 5-year survival rate worldwide. Circular RNAs (circRNAs) regulate cancer development in diverse ways based on their distinct biogenesis mechanisms and expansive regulatory roles. However, currently, there is little research on how exosomal circRNAs are involved in the development of LC. Here, we demonstrated that circPVT1, a circRNA derived from the well-studied long noncoding RNA PVT1, is correlated with disease progression in LC and promotes angiogenesis both in vivo and in vitro. Mechanistically, circPVT1 is loaded into LC cell-secreted exosomes and taken up by vascular epithelium cells. By sponging miR-30c-5p, exosomal circPVT1 promotes Rap1b expression, which dramatically enhances vascular endothelial growth factor receptor 2 and the phosphatidylinositol 3-kinase (PI3K)/AKT pathway activation, ultimately resulting in the induction of angiogenesis. Furthermore, our xenograft models demonstrated that the combination of short hairpin RNA-circPVT1 and cetuximab showed high efficacy in inhibiting tumor growth and angiogenesis. Collectively, these findings uncover a novel mechanism of exosomal circRNA-mediated angiogenesis modulation and provide a preclinical rationale for testing this analogous combination in patients with LC.
Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
The invention provides a microorganism strain of the family trichomonadaceae, a medicament for preventing and/or treating tumors and application thereof, and relates to the technical field of biological medicines. The invention relates to a novel genus-level new species (Lachnospiraceae sp.) of a microorganism strain belonging to the family Lachnospiraceae, wherein the nucleotide sequence of 16S rDNA of the microorganism strain belonging to the family Lachnospiraceae is shown as SEQ ID No. 1; the tumor comprises at least one of the following: liver cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, breast cancer, cervical cancer, ovarian cancer, pancreatic cancer, cholangiocarcinoma, renal cancer, and fibrosarcoma. The invention discovers that the novel intestinal anaerobic microorganism strain Lachnospiraceae sp can inhibit the growth rate of tumor, and can be used for preventing and/or treating tumor. The discovery of the invention enriches the types of strains with anti-tumor effect and has good application prospect.
ZANOSAR sterile powder should be administered intravenously by rapid injection or short/prolonged infusion. It is not active orally. Although it has been administered intraarterially, this is not recommended pending further evaluation of the possibility that adverse renal effects may be evoked more rapidly by this route of administration.

Two different dosage schedules have been employed successfully with ZANOSAR.

Daily Schedule—The recommended dose for daily intravenous administration is 500 mg/m2 of body surface area for five consecutive days every six weeks until maximum benefit or until treatment-limiting toxicity is observed. Dose escalation on this schedule is not recommended.

Weekly Schedule—The recommended initial dose for weekly intravenous administration is 1000 mg/m2 of body surface area at weekly intervals for the first two courses (weeks). In subsequent courses, drug doses may be escalated in patients who have not achieved a therapeutic response and who have not experienced significant toxicity with the previous course of treatment. However, A SINGLE DOSE OF 1500 mg/m2 BODY SURFACE AREA SHOULD NOT BE EXCEEDED as a greater dose may cause azotemia. When administered on this schedule, the median time to onset of response is about 17 days and the median time to maximum response is about 35 days. The median total dose to onset of response is about 2000 mg/m2 body surface area and the median total dose to maximum response is about 4000 mg/m2 body surface area.

The ideal duration of maintenance therapy with ZANOSAR has not yet been clearly established for either of the above schedules.

For patients with functional tumors, serial monitoring of fasting insulin levels allows a determination of biochemical response to therapy. For patients with either functional or nonfunctional tumors, response to therapy can be determined by measurable reductions of tumor size (reduction of organomegaly, masses, or lymph nodes).

Reconstitute ZANOSAR with 9.5 mL of dextrose injection, USP, or 0.9% sodium chloride injection, USP. The resulting pale-gold solution will contain 100 mg of streptozocin and 22 mg of citric acid per mL. Where more dilute infusion solutions are desirable, further dilution in the above vehicles is recommended. The total storage time for streptozocin after it has been placed in solution should not exceed 12 hours. This product contains no preservatives and is not intended as a multiple-dose vial.

Caution in the handling and preparation of the powder and solution should be exercised, and the use of gloves is recommended. If the sterile powder of ZANOSAR or a solution prepared from ZANOSAR contacts the skin or mucosae, immediately wash the affected area with soap and water.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1–7 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
BACKGROUND: Living conditions and socioeconomic status are known to impact individual health and access to medical care. Prior research has validated the Area Deprivation Index (ADI) tool as a measure of socioeconomic disadvantage for a given locality. Living in a neighborhood with a higher ADI score has been associated with increased rates of hospital readmission due to complications following surgery. We set forth to identify the possible associations between a patient's ADI score and postoperative endovascular aneurysm repair (EVAR) outcomes in the Veterans Health Care Administration (VHA).
METHODS: We retrospectively analyzed the outcomes of patients who underwent EVAR from January 2010 to December 2021 at a level 1A VHA Hospital. Patient demographics and intraoperative variables were obtained. ADI score was calculated based on home addresses and resulted in a local score on a scale of 1-10 and a national percentile on a scale of 1-100. We then further stratified these patients into local and national quintile groups. Local ADI 1 included scores of 1-2, and local ADI 5 included scores of 9-10. National ADI 1 comprised scores 1-20, and national ADI 5 scored 81-100. The other scores were equally divided into ADI 2, 3, and 4. Higher ADI scores were associated with lower socioeconomic status. We identified clinical outcomes, including wound infection, respiratory failure, urinary tract infection, acute kidney injury, limb stenosis, readmission, length of stay, and subsequent reintervention rates.
RESULTS: 241 patients underwent EVAR over the time period examined. 57.3% (n = 138) of patients were in quintiles 4 and 5 for local ADI; when national ADI percentiles organized these same patients, 47.3% (n = 114) were in quintiles 4 and 5. Patient demographics did not vary between the local and national groups. We saw no statistically significant difference in intraoperative variables, postoperative complications, readmission, loss to follow-up, or 1-year mortality rates across ADI quintiles at the local or national level. Binary Logistic Regression showed no statistical significance for local and national ADI quintiles for hospital readmission and overall postoperative complications.
CONCLUSIONS: We found that there was no statistical significance between hospital readmission rates or worse surgical outcomes across local and national ADI quintiles. This suggests that the VHA resources and multidisciplinary support may improve care across neighborhoods. This comprehensive care provided at VHA may mitigate postoperative complications in patients undergoing EVARs. Further research is warranted to investigate the role of area deprivation in health care and EVAR outcomes in a veteran population.
Methods for high resolution imaging of a suspected target tissue are encompassed by the invention. Such methods include administering low resolution and high resolution contrast agents specific to targeted cells or tissues. The contrast agents are allowed to bind to the target cells or accumulate in a target tissue. A low resolution imaging technique is used to localize an accumulation of the low resolution contrast agent in a target tissue. A high resolution image of the target tissue is then obtained to localize an accumulation of the higher resolution contrast agent, allowing the generation of a higher resolution image than that obtained by the use of the low resolution contrast agent alone. These methods may utilize nanoparticles optionally in an emulsion as a contrast agent.
In oncologic surgery complete tumor resection is important for treatment outcome and patient survival. When performing cytoreductive surgery (CRS) for peritoneal carcinomatosis of colorectal origin it can sometimes be difficult to distinguish tumor deposits from adhesions and scar tissue. Intraoperative tumor localization and resection can be enhanced using intraoperative imaging techniques (e.g. targeted radioguided or fluorescence guided surgery). A powerful synergy can be achieved by combining radiotracers (e.g. Indium-111) and optical tracers (e.g. IRDye 800CW) conjugated to an antibody against a tumor-associated antigen. Labetuzumab specifically recognises CEA which is expressed on \> 95% of all colorectal cancers. Therefore Indium-111-DOTA-labetuzumab-IRDye800CW is a perfect dual-labeled antibody for dual-modality image-guided surgery in peritoneal carcinomatosis of colorectal origin. The concept has been shown in preclinical studies with mice and the investigators will translate this to the clinic.

Eligible patients with peritoneal carcinomatosis of colorectal origin scheduled for CRS + HIPEC will receive dual-labeled labetuzumab 6-7 days before surgery. At day 4 or 5 a SPECT/CT of the abdomen and thorax will be obtained. Cytoreductive surgery at day 7 will be extended with the use of a near-infrared fluorescence camera and a gamma probe.

The aim of this study is to assess the feasibility and safety of intraoperative dual-modality imaging with Indium-111-DOTA-labetuzumab-IRDye800CW in peritoneal carcinomatosis of colorectal cancer.
A system and computer program product for serving web pages offering fitness and nutritional wellness information. The system includes a plurality of remote computers in communication with a respective plurality of remote users, a central server having a computer program stored in non-transient memory and one or more microprocessors, a network interface in communication with the central server and the plurality of remote computers over a network, and a shared database in communication with the central server. The network interface is configured to receive patient information. The central server is programmed by means of the computer program to receive configuration and setup information, wherein the configuration and setup information includes configuration of user configurable fitness and wellness questions derived from validated questionnaires in a plurality of subspecialty fields, and user configurable correlation rules associated with the fitness and wellness questions, receive and store patient information in the database, wherein the patient information includes responses to the user configurable fitness and wellness questions, correlate the responses based on the user configurable correlation rules to a plurality of functional scores using the one or more microprocessors, provide a health and wellness recommendation based on the functional scores, and transmit one or more web pages, via the network interface, representing the functional scores within the user configurable thresholds, and display the one or more web pages on respective displays of one or more of the plurality of remote computers in communication with respective one or more of the plurality of remote users. The user configurable correlation rules include one or more predefined thresholds. The user configurable threshold includes an upper threshold value and a lower threshold value. Functional scores greater than the upper threshold value are assigned a standard maximum value in the health and wellness recommendation. Functional scores less than the lower thresholds are not included in a final health and wellness recommendation.
Rev. 7E 01/2008 Rx only

C I A 70095A 540A00

LORTAB (pronounced LOR-tab) is used to relieve moderate to moderately severe pain. You should not take LORTAB Elixir if you are allergic to hydrocodone or acetaminophen. The most common side effects of LORTAB Elixir are abdominal pain, dizziness, drowsiness, light-headedness, nausea, shortness of breath, unusual tiredness, and vomiting. Take this medicine as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.
Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After treatment, patients either undergo surgery then receive standard chemotherapy for up to 4 cycles or receive standard chemotherapy within 14 days for up to 4 cycles then undergo surgery in the absence of disease progression or unacceptable toxicity at the discretion of the treating physician.
<P>PROBLEM TO BE SOLVED: To provide a freeze-dried set of a labeled meta-iodobenzylguanidine (MIBG), a method for producing the set, and a method for producing a radioactive iodine label.  <P>SOLUTION: The freeze-dried set of the MIBG includes a first container storing a freeze-dried product of the MIBG, and a second container storing sodium acetate buffer. The method for producing the freeze-dried set includes mixing (labeled meta-iodobenzylguanidine)<SB>3</SB>-sulfate with ammonium sulfate, dissolving the mixture in injectable water, filtering the resultant solution, putting the resultant solution in a container and freeze-drying the solution to provide the first container including the freeze-dried MIBG, and adding the injective water to sodium acetate trihydrate and acetic acid, filtering the resultant mixture and storing the solution to provide the second container. The method for producing the radioactive iodine label includes adding the radioactive iodide ion to the freeze-dried product of the labeled MIBG to react them, and adding the sodium acetate buffer thereto. The activities of the radioactive iodine label are not attenuated before the use because the preparation is simply carried out, and the resultant preparation can be used just after the preparation.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The participants will be randomly assigned to a tVNS or control group. They will visit the lab for four sessions. The main motor task is to trace target trajectories with finger forces. As the pre- and post-tests, all participants will be tested on a force tracing motor task with the left hand. There will be no electrical stimulation during the tests. During the training sessions, all participants will wear surface electrodes on the outer ear. The attachment sites are the tragus or cymba concha (depending on the shape and size of the ear) for the tVNS group and the earlobe for the sham group. The participants will perform finger training to trace target trajectories with their left finger forces. Participants in the tVNS and sham group will receive tVNS and sham stimulation, respectively, after successful finger trials.